DAIC

SEPTEMBER 11, 2024

percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. Digital technologies may reveal it is even more common than the current analysis indicates. The data were standardized to reflect the entire country, and researchers estimated the current national prevalence to be at least 10.55

Atrial Fibrillation 92

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 92

DAIC

SEPTEMBER 11, 2024

percent of the patients treated between 2005 and 2009 to 6.82% of the patients treated between 2015 and 2019. Digital technologies may reveal it is even more common than the current analysis indicates. The data were standardized to reflect the entire country, and researchers estimated the current national prevalence to be at least 10.55

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

Dr. Malcolm Kendrick

OCTOBER 30, 2024

GlaxoSmithKline: $400K Liposcience: £50K HPS2-THRIVE trial of niacin/laropiprant (2005-2015) Merck: £53M plus drug supply HPS3/TIMI55-REVEAL trial of anacetrapib (2010-2022) Merck: £108M plus drug supply HPS 4/TIMI 65 – ORION-4 (2017-ongoing) Novartis Pharma AG Switzerland: £73.7M SEARCH trial of simvastatin dose (1997-2010) Merck: £22.7M

Cholesterol 145

Cholesterol Article Research Diet 145